
Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
7.540
Open
7.540
VWAP
--
Vol
11.70K
Mkt Cap
174.29M
Low
7.540
Amount
--
EV/EBITDA(TTM)
--
Total Shares
759.73M
EV
104.42M
EV/OCF(TTM)
--
P/S(TTM)
--
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N, N-dimethyltryptamine (DMT) and dDMT programs create a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II.CYB005 is in Preclinical stage. It has an intellectual property portfolio in the psychedelic drug development sector with over 80 patents granted and over 230 patent applications pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.
Show More
5 Analyst Rating

1133.42% Upside
Wall Street analysts forecast CYBN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CYBN is 93.00 USD with a low forecast of 25.00 USD and a high forecast of 150.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy

1133.42% Upside
Current: 7.540

Low
25.00
Averages
93.00
High
150.00

1133.42% Upside
Current: 7.540

Low
25.00
Averages
93.00
High
150.00
Canaccord
Buy
downgrade
$73 -> $70
2025-07-08
Reason
Canaccord
Price Target
$73 -> $70
2025-07-08
downgrade
Buy
Reason
Canaccord lowered the firm's price target on Cybin to $70 from $73 and keeps a Buy rating on the shares. The firm noted they recently reported its F4Q25 results and operating expenses came in close to estimates. The key update were that the company is on track to complete its Phase 2 study for CYB004 (deuterated DMT) for generalized anxiety disorder (GAD) in mid- C2025E; and report Phase 3 data for CYB003 (deuterated psilocin analog) for major depressive disorder (MDD) in C2026E. Canaccord continues to believe Cybin is significantly undervalued ahead of data.
Lucid Capital
NULL
to
Buy
initiated
$106
2025-06-06
Reason
Lucid Capital
Price Target
$106
2025-06-06
initiated
NULL
to
Buy
Reason
Lucid Capital initiated coverage of Cybin with a Buy rating and $106 price target. Cybin is developing alternative formulations and derivatives of psychedelic drugs, the analyst tells investors in a research note. The firm points out the Drug Enforcement Agency classifies both of Cybin's drugs as Schedule I, meaning "drugs with no currently accepted medical use and high potential for abuse."
Guggenheim
Eddie Hickman
Strong Buy
Initiates
$35
2025-03-13
Reason
Guggenheim
Eddie Hickman
Price Target
$35
2025-03-13
Initiates
Strong Buy
Reason
Guggenheim initiated coverage of Cybin with a Buy rating and $35 price target.
HC Wainwright & Co.
Patrick Trucchio
Strong Buy
Maintains
$190 → $150
2025-02-13
Reason
HC Wainwright & Co.
Patrick Trucchio
Price Target
$190 → $150
2025-02-13
Maintains
Strong Buy
Reason
Canaccord Genuity
Sumant Kulkarni
Strong Buy
Maintains
$86 → $73
2025-02-12
Reason
Canaccord Genuity
Sumant Kulkarni
Price Target
$86 → $73
2025-02-12
Maintains
Strong Buy
Reason
Canaccord analyst Sumant Kulkarni lowered the firm's price target on Cybin to $73 from $86 and keeps a Buy rating on the shares. The firm noted they reported Q3 results but said the key update was that the company now expects Phase 2 proof-of-concept efficacy/safety data for CYB004 (deuterated DMT) in generalized anxiety disorder (GAD) in C1H25 versus the previous C1Q25.
Canaccord Genuity
Sumant Kulkarni
Strong Buy
Maintains
$86
2024-11-19
Reason
Canaccord Genuity
Sumant Kulkarni
Price Target
$86
2024-11-19
Maintains
Strong Buy
Reason
Canaccord lowered the firm's price target on Cybin to $86 from $96 and keeps a Buy rating on the shares. The firm said they reported results and he key update was that the company has started its PARADIGM Phase 3 program for CYB003 (deuterated psilocybin analog) as an adjunct treatment for major depressive disorder (MDD).
See All Ratings
Valuation Metrics
The current forward P/E ratio for Cybin Inc (CYBN.A) is -2.72, compared to its 5-year average forward P/E of -4.14. For a more detailed relative valuation and DCF analysis to assess Cybin Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-4.14
Current PE
-2.72
Overvalued PE
-1.94
Undervalued PE
-6.34
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-9.61
Current EV/EBITDA
-1.11
Overvalued EV/EBITDA
0.88
Undervalued EV/EBITDA
-20.09
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
56.87
Current PS
0.00
Overvalued PS
292.28
Undervalued PS
-178.55
Financials
Annual
Quarterly
FY2025Q4
N/A
Total Revenue
FY2025Q4
YoY :
+32.06%
-33.27M
Operating Profit
FY2025Q4
YoY :
+43.25%
-30.58M
Net Income after Tax
FY2025Q4
YoY :
-7.59%
-1.46
EPS - Diluted
FY2025Q4
YoY :
+6.09%
-22.20M
Free Cash Flow
FY2025Q4
N/A
Gross Profit Margin - %
FY2025Q4
N/A
FCF Margin - %
FY2025Q4
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
51.9K
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
CYBN News & Events
Events Timeline
2025-07-17 (ET)
2025-07-17
07:37:22
Cybin receives UK MHRA approval to commence EMBRACE study

2025-06-30 (ET)
2025-06-30
22:22:13
Cybin offers up to $500M in convertible debentures

2025-06-24 (ET)
2025-06-24
14:55:18
Mike Davis to become CDER deputy director, Pink Sheet's Gingery says


Sign Up For More Events
Sign Up For More Events
News
3.5
07-20Yahoo FinanceWeekly Roundup on the Cannabis Sector & Psychedelic Sector
9.0
07-17NewsfilterCybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
8.5
07-01NewsfilterREPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures
Sign Up For More News
People Also Watch

ACRV
Acrivon Therapeutics Inc
1.330
USD
0.00%

STFS
Star Fashion Culture Holdings Ltd
1.860
USD
+1.09%

CCRD
CoreCard Corp
26.490
USD
+0.42%

RCKY
Rocky Brands Inc
29.910
USD
+30.16%

TCX
Tucows Inc
19.250
USD
0.00%

ISSC
Innovative Solutions and Support Inc
15.050
USD
0.00%

UAMY
United States Antimony Corp
3.170
USD
+3.26%

CMCL
Caledonia Mining Corporation PLC
20.020
USD
-3.33%
FAQ

What is Cybin Inc (CYBN) stock price today?
The current price of CYBN is 7.54 USD — it has decreased -0.4 % in the last trading day.

What is Cybin Inc (CYBN)'s business?

What is the price predicton of CYBN Stock?

What is Cybin Inc (CYBN)'s revenue for the last quarter?

What is Cybin Inc (CYBN)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Cybin Inc (CYBN)'s fundamentals?

How many employees does Cybin Inc (CYBN). have?
